Abstract
This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.
Original language | English |
---|---|
Pages (from-to) | 365-368 |
Number of pages | 4 |
Journal | Blood Transfusion |
Volume | 15 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2017 |
Keywords
- Bleeding
- Haemophilia A
- Inhibitors
- Obizur
- Porcine recombinant FVIII
ASJC Scopus subject areas
- Immunology and Allergy
- Hematology